Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy.
Author
Ridker, Paul MRifai, Nader
MacFadyen, Jean
Glynn, Robert J
Jiao, Lixia
Steg, Ph Gabriel
Miller, Michael
Brinton, Eliot A
Jacobson, Terry A
Tardif, Jean-Claude
Ballantyne, Christie M
Mason, R Preston
Bhatt, Deepak L
Date
2022-06-28Journal
CirculationPublisher
American Heart AssociationType
Article
Metadata
Show full item recordAbstract
Serum levels of interleukin-1β, interleukin-6, high-sensitivity C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2 (Lp-PLA2) were measured at baseline, at 12 months, at 24 months, and at the end-of-study visit among REDUCE-IT participants with triglyceride levels >135 mg/dL and <500 mg/dL who were randomly allocated to treatment with either 4 grams daily of icosapent ethyl or mineral oil used as a comparator.Identifier to cite or link to this item
http://hdl.handle.net/10713/19329ae974a485f413a2113503eed53cd6c53
10.1161/CIRCULATIONAHA.122.059410
Scopus Count
Collections
Related articles
- Letter by Sherratt Regarding Article, "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy".
- Authors: Sherratt SCR
- Issue date: 2022 Nov 15
- Letter by Lakshmanan et al Regarding Article "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy".
- Authors: Lakshmanan S, Budoff MJ, Nelson JR
- Issue date: 2022 Nov 15
- Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
- Authors: Miller M, Ballantyne CM, Bays HE, Granowitz C, Doyle RT Jr, Juliano RA, Philip S
- Issue date: 2019 Sep 1
- Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
- Authors: Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT Jr, Juliano RA, Granowitz C
- Issue date: 2019 Aug
- Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
- Authors: Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN
- Issue date: 2013 Jul 9